
When your asthma symptoms flare up, your albuterol-only rescue inhaler can relieve airway tightening, but it does not treat the inflammation that can be an underlying cause.
Treating both symptoms and inflammation with rescue is supported by asthma experts.
AIRSUPRA is the first and only FDA-approved asthma rescue designed to treat both symptoms and inflammation


is a short-acting beta-agonist, or SABA, a medicine used to widen airways to help treat symptoms

is an inhaled corticosteroid, or ICS, that addresses airway inflammation
AIRSUPRA is a rescue inhaler and is not intended to replace your daily maintenance therapy.
*Asthma attacks = sudden severe breathing problems.
Treating symptoms and inflammation with rescue is consistent with asthma expert recommendations.
In a clinical trial† of people with moderate to severe asthma who were taking a daily maintenance therapy, AIRSUPRA helped:
Reduce the risk of an attack
28%
reduction
in risk of severe asthma attack vs albuterol‡
Reduce yearly steroid dose
32%
reduction
in yearly steroid dose vs albuterol§║
Your results may vary.
In a clinical trial¶ of people with mild asthma, AIRSUPRA helped:
Reduce the risk of an attack
46%
reduction
in risk of severe asthma attack vs albuterol#
Reduce yearly steroid dose
63%
reduction
in yearly steroid dose vs albuterol**††
Your results may vary.
Most common side effects of AIRSUPRA |
||
|---|---|---|
| AIRSUPRA 1015 patients |
Albuterol 1015 patients |
|
| Headache | 44 (4.3%) | 50 (4.9%) |
| Oral thrush | 13 (1.3%) | 5 (0.5%) |
| Cough | 10 (1.0%) | 11 (1.1%) |
See additional safety information.
Safety results shown for AIRSUPRA and albuterol are for patients ≥12 years old. AIRSUPRA is not approved for patients 12 to 17 years of age.
†A study (≥24 weeks duration) evaluated the use of as-needed AIRSUPRA vs as-needed albuterol in patients with symptomatic moderate to severe asthma taking ICS-containing maintenance therapy with or without an additional controller medicine.
‡Time to first severe asthma attack was used to determine the reduction in risk of an asthma attack for AIRSUPRA vs albuterol. A severe asthma attack was defined as asthma symptoms that required steroids for ≥3 days, an ER or urgent care visit that required steroids for ≥3 days, or a hospitalization due to asthma.
§20% of adults on AIRSUPRA 180/160 mcg and 26% of adults on albuterol 180 mcg received steroid pills or injections due to asthma.
║Mean reduction of 40.5 mg of steroids per patient (86.6 mg with AIRSUPRA and 127.1 mg with albuterol). Doses are in mg of prednisone and were rounded to the nearest whole number in the AIRSUPRA Prescribing Information.
¶A study (≥12 weeks duration) evaluated the use of as-needed AIRSUPRA vs as-needed albuterol in patients with mild asthma, 26% of whom continued their maintenance therapy.
#Time to first severe asthma attack was used to determine the reduction in risk of an asthma attack for AIRSUPRA vs albuterol. A severe asthma attack was defined as asthma symptoms that required steroids for ≥3 days, an ER or urgent care visit that required steroids for ≥3 days, or a hospitalization or death due to asthma.
††Mean reduction of 40.0 mg of steroids per patient (23.0 mg with AIRSUPRA and 63.0 mg with albuterol). Doses are in mg of prednisone and were rounded to the nearest whole number in the AIRSUPRA Prescribing Information.


*Asthma attacks = sudden severe breathing problems.
Remember: Always talk to your doctor if you have questions about your asthma or treatment options.
Sign up to receive tips to manage your asthma and more
All fields with an asterisk (*) are required.
By completing this registration, you confirm that you are at least 18 years old, agree to receive information about AIRSUPRA, and may receive information about other respiratory medicines and services related to your condition which includes, but is not limited to, educational and promotional materials, special offers and services, and for market research purposes, which includes contacting you to participate in focus groups, surveys, or interviews. This may include AstraZeneca or a third party working on AstraZeneca’s behalf contacting you by telephone, email, and text message regarding AstraZeneca support programs that may be of interest to you. Information provided by AstraZeneca does not take the place of talking to your healthcare provider about your treatment or condition. If you no longer want to receive health-related materials, call 1-800-236-9933. Please visit www.azprivacynotice.com to review our Privacy Notice.
Remember: Always talk to your doctor if you have questions about your asthma or treatment options.
Remember: Always talk to your doctor if you have questions about your asthma or treatment options.
Click below to begin the medical questionnaire. Once complete, the results can be sent to your doctor.
AIRSUPRA combines 2 medicines to be used as needed as a rescue inhaler in people 18 years of age and older to:
Please see full Prescribing Information and Patient Information and discuss with your doctor.
You may report side effects related to AstraZeneca products.